Akari Therapeutics is progressing its lead antibody drug conjugate (ADC) candidate, AKTX-101, which uses a novel RNA splicing disrupting payload called PH1, toward Phase 1 clinical trials planned for mid-2027. This new payload targets cancer cells differently from existing ADCs, addressing resistance issues seen with current therapies. The company highlights growing industry interest in novel ADC payloads and is conducting necessary safety studies and manufacturing scale-up. Akari also explores strategic partnerships to expand its payload platform and pipeline potential.
Akari Therapeutics is progressing its novel ADC candidate AKTX-101 toward clinical trials. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 15, 2026 19:31 WIB: of 150 priced US health stocks, 95 rose and 46 fell today. Notable movers include Smith & Nephew plc (SNN) at USD 28.60 with a 1-day change of +2.58% and a typical hold time of 121 days, Takeda Pharmaceutical Company Limited (TAK) at USD 19.50 with a +2.58% change and a typical hold time of 6 days, and Tilray Brands Inc (TLRY) at USD 3.06 with a -2.55% change, Pluang order activity showing 16% sell and 84% buy, and a typical hold time of 31 days.
Alignment Health Plan will expand its Medicare Advantage coverage to Bexar and Comal counties in San Antonio starting January 1, 2027, providing access to coordinated care and trusted local providers for over 392,000 Medicare beneficiaries. This expa...
Interactive Brokers is set to report Q3 2026 earnings of $0.67 per share and revenue of $1.86 billion, reflecting year-over-year growth of about 16% in earnings and 13.5% in revenue. Growth is driven by increased trading activity, more client account...
CareCloud, a leader in AI-powered healthcare technology and revenue cycle management, will announce its financial results for Q3 2026 on November 5 before the market opens. The company will host a conference call at 8:30 a.m. ET to discuss the result...
Morgan Stanley analyst Joseph Moore lowered IonQ's price target from $49 to $43 following the company's announcement of a $2 billion financing deal with Heights Capital Management. The deal involves issuing 20.5 million new shares and 29.5 million pr...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed its share transactions on October 14, 2026. The bank purchased 195,636 ordinary shares at prices between 1093 and 1093.1, and sold 188,669 shares at prices ranging from...
